<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">33389754</PMID><DateCompleted><Year>2021</Year><Month>05</Month><Day>25</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>31</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8249</ISSN><JournalIssue CitedMedium="Internet"><Volume>89</Volume><Issue>4</Issue><PubDate><Year>2021</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Annals of neurology</Title><ISOAbbreviation>Ann Neurol</ISOAbbreviation></Journal><ArticleTitle>The Effect of SMN Gene Dosage on ALS Risk and Disease Severity.</ArticleTitle><Pagination><StartPage>686</StartPage><EndPage>697</EndPage><MedlinePgn>686-697</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/ana.26009</ELocationID><Abstract><AbstractText Label="OBJECTIVE">The role of the survival of motor neuron (SMN) gene in amyotrophic lateral sclerosis (ALS) is unclear, with several conflicting reports. A decisive result on this topic is needed, given that treatment options are available now for SMN deficiency.</AbstractText><AbstractText Label="METHODS">In this largest multicenter case control study to evaluate the effect of SMN1 and SMN2 copy numbers in ALS, we used whole genome sequencing data from Project MinE data freeze 2. SMN copy numbers of 6,375 patients with ALS and 2,412 controls were called from whole genome sequencing data, and the reliability of the calls was tested with multiplex ligation-dependent probe amplification data.</AbstractText><AbstractText Label="RESULTS">The copy number distribution of SMN1 and SMN2 between cases and controls did not show any statistical differences (binomial multivariate logistic regression SMN1 p = 0.54 and SMN2 p = 0.49). In addition, the copy number of SMN did not associate with patient survival (Royston-Parmar; SMN1 p = 0.78 and SMN2 p = 0.23) or age at onset (Royston-Parmar; SMN1 p = 0.75 and SMN2 p = 0.63).</AbstractText><AbstractText Label="INTERPRETATION">In our well-powered study, there was no association of SMN1 or SMN2 copy numbers with the risk of ALS or ALS disease severity. This suggests that changing SMN protein levels in the physiological range may not modify ALS disease course. This is an important finding in the light of emerging therapies targeted at SMN deficiencies. ANN NEUROL 2021;89:686-697.</AbstractText><CopyrightInformation>&#xa9; 2021 The Authors. Annals of Neurology published by Wiley Periodicals LLC on behalf of American Neurological Association.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Moisse</LastName><ForeName>Matthieu</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-8880-9311</Identifier><AffiliationInfo><Affiliation>Departments of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwamborn</LastName><ForeName>Ramona A J</ForeName><Initials>RAJ</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Vugt</LastName><ForeName>Joke</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0002-4161-4004</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van der Spek</LastName><ForeName>Rick</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0001-9983-204X</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Rheenen</LastName><ForeName>Wouter</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-5860-1533</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenna</LastName><ForeName>Brendan</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Van Eijk</LastName><ForeName>Kristel</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kenna</LastName><ForeName>Kevin</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Corcia</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-1625-8845</Identifier><AffiliationInfo><Affiliation>Centre SLA, CHRU de Tours, Tours, France.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>UMR 1253, iBrain, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Couratier</LastName><ForeName>Philippe</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9562-856X</Identifier><AffiliationInfo><Affiliation>Centre SLA, CHRU de Tours, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vourc'h</LastName><ForeName>Patrick</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-7960-8139</Identifier><AffiliationInfo><Affiliation>UMR 1253, iBrain, Universit&#xe9; de Tours, Inserm, Tours, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hardiman</LastName><ForeName>Orla</ForeName><Initials>O</Initials><Identifier Source="ORCID">0000-0003-2610-1291</Identifier><AffiliationInfo><Affiliation>Academic Unit of Neurology, Trinity College Dublin, Trinity Biomedical Sciences Institute, Dublin, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>McLaughin</LastName><ForeName>Russell</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3915-2135</Identifier><AffiliationInfo><Affiliation>Complex Trait Genomics Laboratory, Smurfit Institute of Genetics, Trinity College Dublin, Dublin, Republic of Ireland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotkine</LastName><ForeName>Marc</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-2541-6232</Identifier><AffiliationInfo><Affiliation>The Agnes Ginges Center for Human Neurogenetics, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drory</LastName><ForeName>Vivian</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Department of Neurology, Tel-Aviv Sourasky Medical Centre, Tel Aviv, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ticozzi</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-5963-7426</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Silani</LastName><ForeName>Vincenzo</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0002-7698-3854</Identifier><AffiliationInfo><Affiliation>Department of Neurology, Stroke Unit and Laboratory of Neuroscience, IRCCS Istituto Auxologico Italiano, Milano, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Pathophysiology and Transplantation, "Dino Ferrari" Center, Universit&#xe0; degli Studi di Milano, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>de Carvalho</LastName><ForeName>Mamede</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0001-7556-0158</Identifier><AffiliationInfo><Affiliation>Instituto de Fisiologia, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mora Pardina</LastName><ForeName>Jes&#xfa;s S</ForeName><Initials>JS</Initials><Identifier Source="ORCID">0000-0001-6633-5354</Identifier><AffiliationInfo><Affiliation>ALS Unit, Hospital San Rafael, Madrid, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Povedano</LastName><ForeName>Monica</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Servei de Neurologia, HUB-IDIBELL, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Andersen</LastName><ForeName>Peter M</ForeName><Initials>PM</Initials><Identifier Source="ORCID">0000-0003-0094-5429</Identifier><AffiliationInfo><Affiliation>Department of Clinical Science, Neurosciences, Ume&#xe5; University, Ume&#xe5;, Sweden.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Weber</LastName><ForeName>Markus</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Neuromuscular Diseases Unit/ALS Clinic, St. Gallen, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ba&#x15f;ak</LastName><ForeName>Nazli A</ForeName><Initials>NA</Initials><Identifier Source="ORCID">0000-0001-6977-2517</Identifier><AffiliationInfo><Affiliation>Ko&#xe7; University, School of Medicine, KUTTAM-NDAL, Istanbul, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Xiao</ForeName><Initials>X</Initials><Identifier Source="ORCID">0000-0002-1432-268X</Identifier><AffiliationInfo><Affiliation>Illumina Inc., San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eberle</LastName><ForeName>Michael A</ForeName><Initials>MA</Initials><Identifier Source="ORCID">0000-0001-8965-1253</Identifier><AffiliationInfo><Affiliation>Illumina Inc., San Diego, CA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Al-Chalabi</LastName><ForeName>Ammar</ForeName><Initials>A</Initials><Identifier Source="ORCID">0000-0002-4924-7712</Identifier><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Chris</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, King's College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Shaw</LastName><ForeName>Pamela J</ForeName><Initials>PJ</Initials><Identifier Source="ORCID">0000-0002-8925-2567</Identifier><AffiliationInfo><Affiliation>Sheffield Institute for Translational Neuroscience (SITraN), University of Sheffield, Sheffield, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morrison</LastName><ForeName>Karen E</ForeName><Initials>KE</Initials><Identifier Source="ORCID">0000-0003-0216-5717</Identifier><AffiliationInfo><Affiliation>School of Medicine, Dentistry, and Biomedical Sciences, Queen's University Belfast, Belfast, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Landers</LastName><ForeName>John E</ForeName><Initials>JE</Initials><Identifier Source="ORCID">0000-0001-8084-5043</Identifier><AffiliationInfo><Affiliation>Department of Neurology, University of Massachusetts Medical School, Worcester, MA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Glass</LastName><ForeName>Jonathan D</ForeName><Initials>JD</Initials><Identifier Source="ORCID">0000-0002-3295-4971</Identifier><AffiliationInfo><Affiliation>Department Neurology, Emory University School of Medicine, Atlanta, GA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robberecht</LastName><ForeName>Wim</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Departments of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van Es</LastName><ForeName>Michael</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0002-7709-5883</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>van den Berg</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-5203-9674</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Veldink</LastName><ForeName>Jan</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0001-5572-9657</Identifier><AffiliationInfo><Affiliation>Department of Neurology, UMC Utrecht Brain Center, Utrecht University, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Van Damme</LastName><ForeName>Philip</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0002-4010-2357</Identifier><AffiliationInfo><Affiliation>Departments of Neurosciences, Experimental Neurology, and Leuven Brain Institute (LBI), KU Leuven - University of Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Laboratory of Neurobiology, VIB, Center for Brain and Disease Research, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Hospitals Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Project MinE Sequencing Consortium</CollectiveName><AffiliationInfo><Affiliation>Project MinE Sequencing Consortium, Utrecht, The Netherlands.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MR/L501529/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>R56 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01 NS073873</GrantID><Acronym>NS</Acronym><Agency>NINDS NIH HHS</Agency><Country>United States</Country></Grant><Grant><Acronym>WT_</Acronym><Agency>Wellcome Trust</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>ALCHALABI-DOBSON/APR14/829-791</GrantID><Acronym>MNDA_</Acronym><Agency>Motor Neurone Disease Association</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>G0600974</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant><Grant><GrantID>MR/R024804/1</GrantID><Acronym>MRC_</Acronym><Agency>Medical Research Council</Agency><Country>United Kingdom</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>01</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann Neurol</MedlineTA><NlmUniqueID>7707449</NlmUniqueID><ISSNLinking>0364-5134</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C526471">SMN1 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C526477">SMN2 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055533">Survival of Motor Neuron 1 Protein</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D055540">Survival of Motor Neuron 2 Protein</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018628" MajorTopicYN="N">Gene Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015203" MajorTopicYN="N">Reproducibility of Results</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012307" MajorTopicYN="N">Risk Factors</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055533" MajorTopicYN="N">Survival of Motor Neuron 1 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055540" MajorTopicYN="N">Survival of Motor Neuron 2 Protein</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000073336" MajorTopicYN="N">Whole Genome Sequencing</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>X.C. and M.A.E. are employees of Illumina Inc.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>12</Month><Day>29</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>9</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>12</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>1</Month><Day>4</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>5</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>1</Month><Day>3</Day><Hour>20</Hour><Minute>42</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">33389754</ArticleId><ArticleId IdType="pmc">PMC8048961</ArticleId><ArticleId IdType="doi">10.1002/ana.26009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Van Damme P, Robberecht W, Van Den Bosch L. Modelling amyotrophic lateral sclerosis: progress and possibilities. Dis Model Mech 2017;10:537&#x2013;549.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5451175</ArticleId><ArticleId IdType="pubmed">28468939</ArticleId></ArticleIdList></Reference><Reference><Citation>Hagenacker T, Wurster CD, G&#xfc;nther R, et al. Nusinersen in adults with 5q spinal muscular atrophy: a non&#x2010;interventional, multicentre, observational cohort study. Lancet Neurol 2020;19:317&#x2013;325.</Citation><ArticleIdList><ArticleId IdType="pubmed">32199097</ArticleId></ArticleIdList></Reference><Reference><Citation>Pupillo E, Messina P, Logroscino G, et al. Long&#x2010;term survival in amyotrophic lateral sclerosis: a population&#x2010;based study. Ann Neurol 2014;75:287&#x2013;297.</Citation><ArticleIdList><ArticleId IdType="pubmed">24382602</ArticleId></ArticleIdList></Reference><Reference><Citation>Masrori P, Van Damme P. Amyotrophic lateral sclerosis: a clinical review. Eur J Neurol 2020;27:1918&#x2013;1929.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7540334</ArticleId><ArticleId IdType="pubmed">32526057</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogh I, Lin K, Tiloca C, et al. Association of a locus in the CAMTA1 gene with survival in patients with sporadic amyotrophic lateral sclerosis. JAMA Neurol 2016;73:812&#x2013;820.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5556366</ArticleId><ArticleId IdType="pubmed">27244217</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X&#x2010;B, Cui N&#x2010;H, Gao J&#x2010;J, et al. SMN1 duplications contribute to sporadic amyotrophic lateral sclerosis susceptibility: evidence from a meta&#x2010;analysis. J Neurol Sci 2014;340:63&#x2013;68.</Citation><ArticleIdList><ArticleId IdType="pubmed">24630593</ArticleId></ArticleIdList></Reference><Reference><Citation>Blauw HM, Barnes CP, van Vught PWJ, et al. SMN1 gene duplications are associated with sporadic ALS. Neurology 2012;78:776&#x2013;780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3304946</ArticleId><ArticleId IdType="pubmed">22323753</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Ingre C, Blasco H, et al. Homozygous SMN2 deletion is a protective factor in the Swedish ALS population. Eur J Hum Genet 2012;20:588&#x2013;591.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3330228</ArticleId><ArticleId IdType="pubmed">22274580</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, Kalmijn S, Van der Hout AH, et al. SMN genotypes producing less SMN protein increase susceptibility to and severity of sporadic ALS. Neurology 2005;65:820&#x2013;825.</Citation><ArticleIdList><ArticleId IdType="pubmed">16093455</ArticleId></ArticleIdList></Reference><Reference><Citation>Veldink JH, van den Berg LH, Cobben JM, et al. Homozygous deletion of the survival motor neuron 2 gene is a prognostic factor in sporadic ALS. Neurology 2001;56:749&#x2013;752.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274309</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Camu W, Praline J, et al. The importance of the SMN genes in the genetics of sporadic ALS. Amyotroph Lateral Scler 2009;10:436&#x2013;440.</Citation><ArticleIdList><ArticleId IdType="pubmed">19922137</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Camu W, Halimi J&#x2010;M, et al. SMN1 gene, but not SMN2, is a risk factor for sporadic ALS. Neurology 2006;67:1147&#x2013;1150.</Citation><ArticleIdList><ArticleId IdType="pubmed">16931506</ArticleId></ArticleIdList></Reference><Reference><Citation>Corcia P, Mayeux&#x2010;Portas V, Khoris J, et al. Abnormal SMN1 gene copy number is a susceptibility factor for amyotrophic lateral sclerosis. Ann Neurol 2002;51:243&#x2013;246.</Citation><ArticleIdList><ArticleId IdType="pubmed">11835381</ArticleId></ArticleIdList></Reference><Reference><Citation>Gamez J, Barcel&#xf3; MJ, Mu&#xf1;oz X, et al. Survival and respiratory decline are not related to homozygous SMN2 deletions in ALS patients. Neurology 2002;59:1456&#x2013;1460.</Citation><ArticleIdList><ArticleId IdType="pubmed">12427907</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee J&#x2010;B, Lee K&#x2010;A, Hong J&#x2010;M, et al. Homozygous SMN2 deletion is a major risk factor among twenty&#x2010;five Korean sporadic amyotrophic lateral sclerosis patients. Yonsei Med J 2012;53:53&#x2013;57.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3250330</ArticleId><ArticleId IdType="pubmed">22187232</ArticleId></ArticleIdList></Reference><Reference><Citation>Harada Y, Sutomo R, Sadewa AH, et al. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: three SMN2 copies fail to rescue some patients from the disease severity. J Neurol 2002;249:1211&#x2013;1219.</Citation><ArticleIdList><ArticleId IdType="pubmed">12242541</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun Y, Grimmler M, Schwarzer V, et al. Molecular and functional analysis of intragenic SMN1 mutations in patients with spinal muscular atrophy. Hum Mutat 2005;25:64&#x2013;71.</Citation><ArticleIdList><ArticleId IdType="pubmed">15580564</ArticleId></ArticleIdList></Reference><Reference><Citation>Rochette CF, Gilbert N, Simard LR. SMN gene duplication and the emergence of the SMN2 gene occurred in distinct hominids: SMN2 is unique to Homo sapiens . Hum Genet 2001;108:255&#x2013;266.</Citation><ArticleIdList><ArticleId IdType="pubmed">11354640</ArticleId></ArticleIdList></Reference><Reference><Citation>Hua Y, Sahashi K, Hung G, et al. Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model. Genes Dev 2010;24:1634&#x2013;1644.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2912561</ArticleId><ArticleId IdType="pubmed">20624852</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendell JR, Al&#x2010;Zaidy S, Shell R, et al. Single&#x2010;dose gene&#x2010;replacement therapy for spinal muscular atrophy. N Engl J Med 2017;377:1713&#x2013;1722.</Citation><ArticleIdList><ArticleId IdType="pubmed">29091557</ArticleId></ArticleIdList></Reference><Reference><Citation>Project MinE ALS Sequencing Consortium . Project MinE: study design and pilot analyses of a large&#x2010;scale whole&#x2010;genome sequencing study in amyotrophic lateral sclerosis. Eur J Hum Genet 2018;26:1537&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6138692</ArticleId><ArticleId IdType="pubmed">29955173</ArticleId></ArticleIdList></Reference><Reference><Citation>Kopanos C, Tsiolkas V, Kouris A, et al. VarSome: the human genomic variant search engine. Bioinformatics 2019;35:1978&#x2013;1980.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6546127</ArticleId><ArticleId IdType="pubmed">30376034</ArticleId></ArticleIdList></Reference><Reference><Citation>Dolzhenko E, Deshpande V, Schlesinger F, et al. ExpansionHunter: a sequence&#x2010;graph&#x2010;based tool to analyze variation in short tandem repeat regions. Bioinformatics 2019;35:4754&#x2013;4756.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6853681</ArticleId><ArticleId IdType="pubmed">31134279</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen X, BioResource N, Sanchis&#x2010;Juan A, et al. Spinal muscular atrophy diagnosis and carrier screening from genome sequencing data. Genet Med 2020;22:945&#x2013;953.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200598</ArticleId><ArticleId IdType="pubmed">32066871</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoon S, Lee CH, Lee K&#x2010;A. Determination of SMN1 and SMN2 copy numbers in a Korean population using multiplex ligation&#x2010;dependent probe amplification. Korean J Lab Med 2010;30:93&#x2013;96.</Citation><ArticleIdList><ArticleId IdType="pubmed">20197730</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang P, Li L, Zeng J, et al. Molecular characterization and copy number of SMN1, SMN2 and NAIP in Chinese patients with spinal muscular atrophy and unrelated healthy controls. BMC Musculoskelet Disord 2015;16:11.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4328246</ArticleId><ArticleId IdType="pubmed">25888055</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Y, Ge X, Meng L, et al. The next generation of population&#x2010;based spinal muscular atrophy carrier screening: comprehensive pan&#x2010;ethnic SMN1 copy&#x2010;number and sequence variant analysis by massively parallel sequencing. Genet Med 2017;19:936&#x2013;944.</Citation><ArticleIdList><ArticleId IdType="pubmed">28125085</ArticleId></ArticleIdList></Reference><Reference><Citation>Royston P, Parmar MKB. Flexible parametric proportional&#x2010;hazards and proportional&#x2010;odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002;21:2175&#x2013;2197.</Citation><ArticleIdList><ArticleId IdType="pubmed">12210632</ArticleId></ArticleIdList></Reference><Reference><Citation>Akimoto C, Volk AE, van Blitterswijk M, et al. A blinded international study on the reliability of genetic testing for GGGGCC&#x2010;repeat expansions in C9orf72 reveals marked differences in results among 14 laboratories. J Med Genet 2014;51:419&#x2013;424.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4033024</ArticleId><ArticleId IdType="pubmed">24706941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowerman M, Murray LM, Scamps F, et al. Pathogenic commonalities between spinal muscular atrophy and amyotrophic lateral sclerosis: converging roads to therapeutic development. Eur J Med Genet 2018;61:685&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">29313812</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon CM, Dai Y, Van Alstyne M, et al. Converging mechanisms of p53 activation drive motor neuron degeneration in spinal muscular atrophy. Cell Rep 2017;21:3767&#x2013;3780.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5747328</ArticleId><ArticleId IdType="pubmed">29281826</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos DM, d&#x2019;Ydewalle C, Gabbeta V, et al. Age&#x2010;dependent SMN expression in disease&#x2010;relevant tissue and implications for SMA treatment. J Clin Invest. 2019;129:4817&#x2013;4831.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6819103</ArticleId><ArticleId IdType="pubmed">31589162</ArticleId></ArticleIdList></Reference><Reference><Citation>Czech C, Tang W, Bugawan T, et al. Biomarker for spinal muscular atrophy: expression of SMN in peripheral blood of SMA patients and healthy controls. PLOS ONE. 2015;10:e0139950.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4607439</ArticleId><ArticleId IdType="pubmed">26468953</ArticleId></ArticleIdList></Reference><Reference><Citation>Sumner CJ, Kolb SJ, Harmison GG, et al. SMN mRNA and protein levels in peripheral blood. Neurology. 2006;66:1067&#x2013;1073.</Citation><ArticleIdList><ArticleId IdType="pubmed">16481599</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez&#x2010;Muela N, Litterman NK, Norabuena EM, et al. Single&#x2010;cell analysis of SMN reveals its broader role in neuromuscular disease. Cell Rep 2017;18:1484&#x2013;1498.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5463539</ArticleId><ArticleId IdType="pubmed">28178525</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>